Skip to main content
TipRanks
Go Ultimate75% OFF

Clorox (CLX) AI Stock Analysis

3,291 Followers
CLX

Clorox

(NYSE:CLX)

Select Model
Rating:64Neutral
Price Target:$117.00â–²(9.65% Upside)
Action:reiterated
Date:11/04/26

CLX scores 64 mainly due to improving operating results and free-cash-flow generation, tempered by a pressured balance sheet with high leverage and slightly negative equity. Technicals are supportive with positive momentum and price above key averages, while valuation is helped by a moderate P/E and a high dividend yield. Earnings-call guidance was constructive but constrained by near-term inflation and margin pressure.

Positive Factors
Improving Revenue and Cash GenerationImproving revenue alongside solid gross and operating margins indicates recovering demand and operational resilience. Rising free cash flow adds internal funding capacity for brand investment, innovation, integration and debt service, supporting the durability of Clorox’s business model over the coming quarters.
Negative Factors
High Leverage and Negative EquityHigh debt relative to assets and negative equity materially reduce financial flexibility. Although Clorox remains profitable, substantial leverage can constrain investment, slow deleveraging and leave the company more exposed to weaker operating conditions or sustained cost pressure.

Clorox Key Performance Indicators (KPIs)

Revenue by SegmentHighlights income from different business units, showing which areas drive growth and profitability, and where the company might focus future investments.

-$500.00M$0.00$500.00M$1.00B$1.50B$2.00BMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Health & Wellness and Home Care are the portfolio engines — Health & Wellness shows clear late‑cycle acceleration (the June 2026 lift aligns with the GOJO contribution and strong category share gains), while Home Care’s multi‑quarter share wins underpin durable demand. International and Lifestyle are steady but less dynamic, and the erratic 'Corporate & Other' line reflects acquisition/ERP integration noise and one‑offs. Management warns of front‑loaded >$200M inflation and elevated promotions that will pressure H1 margins, but GOJO synergies and ERP productivity should support margin recovery and stable FCF in H2/FY2027.

Data provided by:The Fly

Clorox (CLX) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%CLX+12.04%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$12.93B
Dividend Yield
4.67%
Average Volume (3M)
3.17M
Price to Earnings (P/E)
19.4
Beta (1Y)
0.28
Revenue Growth
6.28%
EPS Growth
-13.15%
Country
US
Employees
9,200
Sector
Consumer Defensive
Sector Strength
62
Industry
Household & Personal Products

Clorox Business Overview & Revenue Model

Company Description

The Clorox Company is a global manufacturer and marketer of both consumer and professional products, operating through four distinct segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness division offers a ran...

How the Company Makes Money

Clorox makes money primarily by selling branded consumer packaged goods to retail and other distributors, generating revenue when its products are purchased for resale by mass retailers, grocery stores, club stores, drugstores, home improvement retai...

Clorox Earnings Call Summary

Earnings Call Date:Nov 02, 2026(Q1-2027)|% Change Since:18.69%|Next Earnings Date:Feb 04, 2027
Earnings Call SentimentPositive

The call was cautiously optimistic. Clorox reported a better-than-expected start, improving consumption and market-share trends, strong cost savings, positive GOJO integration progress and a robust innovation pipeline. However, these positives are being offset in the near term by $240 million of input cost inflation, front-half gross-margin compression, modest organic sales growth excluding the ERP benefit, elevated competition, consumer value-seeking behavior and continued weakness in Cat Litter. Overall, the highlights outweigh the lowlights, but management remains focused on executing a gradual recovery.

Positive Updates

Better-Than-Expected First-Quarter Performance
Clorox delivered better-than-expected fiscal year 2027 first-quarter results through strong execution and favorable timing benefits. Management said the underlying trajectory is improving, with steady progress in organic sales growth and market share.

Negative Updates

Elevated Input Cost Inflation
Fiscal-year input cost inflation is now expected to be about $240 million, approximately $40 million higher than the initial forecast and about 2.5 times the historical annual average rate. The increase is driven by commodities, resin, supplier costs, transportation and other logistics costs; the outlook assumes an annual average Brent price of around $100.

Company Guidance

Management expects fiscal year organic sales growth of 3.5% to 4.5%, including about 3.5 points of benefit from lapping the ERP transition, or flat to plus 1% excluding the ERP; excluding the ERP, growth is expected to be down slightly in the front half and up slightly in the back half, while category growth is expected to be flat to up 1%. Input cost inflation is expected to be about $240 million, about $40 million more than initially expected and about 2.5x higher our historical annual average rate, assuming Brent annual average price would be around $100, with inflation more pronounced in the first half than in the second half. The company expects gross margin compression on average for the full year, with the front half about 1 point, 1.5 below the average and the back half higher, while SG&A moved from 16% to 15%; the long-term objective remains historical EBIT margin of about 18% and historical gross margin of 43.5% and 44%. Cost synergies from GOJO are estimated at about $50 million, with line of sight to the entire $50 million and potentially more.

Clorox Financial Statement Overview

Summary

Operating performance is improving (TTM revenue +7.1% to $7.20B) with solid profitability (~42% gross margin, ~14.6% operating margin) and constructive, growing free cash flow ($453M, +11.9%). The major offset is balance-sheet risk: high debt ($5.59B) and slightly negative equity (-$39M), which reduces flexibility and keeps financial risk elevated.

Income Statement

72Positive

Balance Sheet

28Negative

Cash Flow

64Positive
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue7.20B6.72B7.10B7.09B7.39B7.11B
Gross Profit3.02B2.84B3.21B3.05B2.91B2.54B
EBITDA1.31B1.17B1.39B723.00M564.00M937.00M
Net Income677.00M587.00M810.00M280.00M149.00M462.00M
Balance Sheet
Total Assets7.83B7.79B5.56B5.75B5.95B6.16B
Cash, Cash Equivalents and Short-Term Investments184.00M143.00M167.00M202.00M367.00M183.00M
Total Debt5.59B5.52B2.88B2.90B2.92B3.10B
Total Liabilities7.71B7.54B5.08B5.26B5.56B5.43B
Stockholders Equity-39.00M90.00M321.00M328.00M220.00M556.00M
Cash Flow
Free Cash Flow453.00M405.00M761.00M483.00M930.00M535.00M
Operating Cash Flow662.00M612.00M981.00M695.00M1.16B786.00M
Investing Cash Flow-2.30B-2.30B-94.00M-175.00M-223.00M-229.00M
Financing Cash Flow1.66B1.67B-924.00M-655.00M-753.00M-689.00M

Clorox Technical Analysis

Technical Analysis SentimentPositive
Last Price106.70

Price Trends

50DMA88.56Positive
100DMA93.09Positive
200DMA96.81Positive

Market Momentum

MACD6.16Negative
RSI72.20Negative
STOCH87.21Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLX, the sentiment is Positive. The current price of 106.70 is above the 20-day moving average (MA) of 96.36, above the 50-day MA of 88.56, and above the 200-day MA of 96.81, indicating a bullish trend. The MACD of 6.16 indicates Negative momentum. The RSI at 72.20 is Negative, neither overbought nor oversold. The STOCH value of 87.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLX.

Clorox Risk Analysis

Clorox disclosed 35 risk factors in its most recent earnings report. Clorox reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Clorox Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

CLX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CHDCHD78Outperform$26.55B34.4418.21%1.09%1.70%2.07%
PGPG72Outperform$398.01B25.4329.55%2.52%3.52%-3.74%
KMBKMB69Neutral$66.37B10.88162.62%4.72%-8.38%67.47%
CLCL67Neutral$79.18B38.711135.82%2.12%5.91%-28.30%
ULUL64Neutral$140.97B14.0058.26%3.30%-17.45%8.84%
CLXCLX64Neutral$12.93B19.38-1920.57%4.67%6.28%-13.15%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%

* Consumer Defensive Sector Average

Performance Comparison

0%20%40%CLXCHDCLKMBPGULDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CLX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CLXClorox Company106.7013.0313.91%
CHDChurch & Dwight Company112.4830.9537.97%
CLColgate-palmolive Company99.6122.9829.99%
KMBKimberly Clark108.1510.7711.06%
PGProcter & Gamble Company171.7228.8820.21%
ULUnilever plc65.314.307.05%

Clorox Corporate Events

Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements

Clorox Reports Strong Fiscal First-Quarter Sales and Earnings Growth

Positive
Nov 2, 2026

Clorox is a household, cleaning and professional-products company serving consumer and healthcare markets in the U.S. and internationally, with brands spanning cleaning, bags and wraps, cat litter, grilling, food, water filtration and natural persona...

Business Operations and StrategyExecutive/Board Changes

Clorox Names Fabian Garcia as Incoming CEO and Chair

Positive
Oct 29, 2026

On October 28, 2026, Clorox’s board appointed veteran consumer products executive Fabian Garcia as CEO and director, effective January 5, 2027, following a search prompted by current CEO and chair Linda Rendle’s decision to step down for health reaso...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026